EIF2A and triple-negative breast carcinoma: It suppressed the migration and invasion of triple-negative breast cancer Hs576T and MDA-MB-231 cells overexpressing ETHE1 (ethylmalonic encephalopathy protein 1), which upregulates eIF2α phosphorylation [192], and diminished the growth and metastatic potential of subcutaneous MDA-MB-231 xenografts in mice either as a single agent or in combination with doxorubicin [193].